Investor relations.
Optimi Health Corp. is a commercial-stage psychedelic drug manufacturer, GMP-licensed by Health Canada, producing MDMA capsules and natural psilocybin extract for regulated treatment programs. The Company supplies finished-dose product to authorized prescribers in Australia under the TGA Authorized Prescriber Scheme. This page provides the official stock, filings, and disclosure channels for investors.
Not yet on file with the SEC. See all filings.
| Product | Australia TGA APS | Canada Health Canada SAP | United States FDA pathway | European Union National schemes |
|---|---|---|---|---|
Natural Psilocybin Extract 4-PO-DMT · Capsule | Shipping Since 2024; routine exports | Supplying Special Access Program | Planned Awaiting federal rescheduling | Evaluating Monitoring national access |
MDMA 60 mg MDMA HCl · Capsule | Shipping Active under APS | Supplying SAP + clinical trials | Planned Awaiting federal rescheduling | Evaluating Monitoring national access |
MDMA 40 mg MDMA HCl · Capsule | Shipping Active under APS | Supplying SAP + clinical trials | Planned Awaiting federal rescheduling | Evaluating Monitoring national access |
Natural Microdose 4-PO-DMT · 1 mg | Shipping Launching 2026 | Supplying Special Access Program | Planned Awaiting federal rescheduling | Evaluating Monitoring national access |
Status reflects current Company operations. Optimi supplies product into regulated access pathways rather than conducting clinical trials as a drug developer. Shipping = routine commercial exports; Supplying = active supply into research programs or special-access pathways; Planned = infrastructure in place, awaiting regulatory access; Evaluating = tracking the jurisdiction.
Receive press releases, filings, and event notifications by email. Confirmation uses a double opt-in and you can unsubscribe from any message we send. We do not share your email address.